Laboratorios Farmaceuticos ROVI SA
OTC:LABFF

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Watchlist
Price: 90.61 USD Market Closed
Market Cap: $4.6B

Gross Margin

63.9%
Current
Improving
by 1.7%
vs 3-y average of 62.1%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
63.9%
=
Gross Profit
€462.5m
/
Revenue
€724.2m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
63.9%
=
Gross Profit
$462.5m
/
Revenue
€724.2m

Peer Comparison

Country Company Market Cap Gross
Margin
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
3.8B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1.1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
564.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
287.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
294.9B USD
Loading...
CH
Novartis AG
SIX:NOVN
229.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
215B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
153.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
98.9B EUR
Loading...

Market Distribution

In line with most companies in Spain
Percentile
68th
Based on 599 companies
68th percentile
63.9%
Low
-178.8% — 38.9%
Typical Range
38.9% — 65.1%
High
65.1% — 192.7%
Distribution Statistics
Spain
Min -178.8%
30th Percentile 38.9%
Median 52.5%
70th Percentile 65.1%
Max 192.7%

Laboratorios Farmaceuticos ROVI SA
Glance View

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

LABFF Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
63.9%
=
Gross Profit
€462.5m
/
Revenue
€724.2m
What is Laboratorios Farmaceuticos ROVI SA's current Gross Margin?

The current Gross Margin for Laboratorios Farmaceuticos ROVI SA is 63.9%, which is above its 3-year median of 62.1%.

How has Gross Margin changed over time?

Over the last 3 years, Laboratorios Farmaceuticos ROVI SA’s Gross Margin has increased from 61.3% to 63.9%. During this period, it reached a low of 59.3% on Dec 31, 2023 and a high of 63.9% on Oct 30, 2025.

Back to Top